secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001437749-25-008777
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma posts FY2024 operating loss of $18.5M; NDA filings for ketamine and bipolar drug anticipated in 2025
--------------------------------------------------------------------------------

- Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.
- Received non-binding terms for NRX-100 license with >$300M milestones plus double-digit royalties.
- Initiated NDA for NRX-100 (IV ketamine) and plans NDA for NRX-101 (bipolar depression); both target PDUFA dates before Dec 31, 2025.
- HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers; negotiating for six more; BTIG engaged as advisor.
- Cash $1.4M at Dec 31, 2024; raised $8.5M in Jan 2025; management expects sufficient cash through end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/0001437749-25-008777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/nrxp20250319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer